| International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2 RG Pertwee, AC Howlett, ME Abood, SPH Alexander, V Di Marzo, ... Pharmacological reviews 62 (4), 588-631, 2010 | 1826 | 2010 |
| The orphan receptor GPR55 is a novel cannabinoid receptor E Ryberg, N Larsson, S Sjögren, S Hjorth, NO Hermansson, J Leonova, ... British journal of pharmacology 152 (7), 1092-1101, 2007 | 1769 | 2007 |
| Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis KM Hallow, G Helmlinger, PJ Greasley, JJV McMurray, DW Boulton Diabetes, Obesity and Metabolism 20 (3), 479-487, 2018 | 390 | 2018 |
| The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo LS Whyte, E Ryberg, NA Sims, SA Ridge, K Mackie, PJ Greasley, ... Proceedings of the national Academy of sciences 106 (38), 16511-16516, 2009 | 371 | 2009 |
| Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes MC Petrie, S Verma, KF Docherty, SE Inzucchi, I Anand, J Bělohlávek, ... Jama 323 (14), 1353-1368, 2020 | 362 | 2020 |
| Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation JJJ Van Giezen, L Nilsson, P Berntsson, BM Wissing, F Giordanetto, ... Journal of thrombosis and haemostasis 7 (9), 1556-1565, 2009 | 337 | 2009 |
| Identification and characterisation of a novel splice variant of the human CB1 receptor E Ryberg, HK Vu, N Larsson, T Groblewski, S Hjorth, T Elebring, ... FEBS letters 579 (1), 259-264, 2005 | 200 | 2005 |
| Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function S Petrykiv, CD Sjöström, PJ Greasley, J Xu, F Persson, HJL Heerspink Clinical Journal of the American Society of Nephrology 12 (5), 751-759, 2017 | 147 | 2017 |
| Myc induces the nucleolin and BN51 genes: possible implications in ribosome biogenesis PJ Greasley, C Bonnard, B Amati Nucleic acids research 28 (2), 446-453, 2000 | 145 | 2000 |
| Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial DZI Cherney, CCJ Dekkers, SJ Barbour, D Cattran, AHA Gafor, ... The Lancet Diabetes & Endocrinology 8 (7), 582-593, 2020 | 141 | 2020 |
| Mutagenesis and modelling of the α1b-adrenergic receptor highlight the role of the helix 3/helix 6 interface in receptor activation PJ Greasley, F Fanelli, O Rossier, L Abuin, S Cotecchia Molecular pharmacology 61 (5), 1025-1032, 2002 | 138 | 2002 |
| Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF AM Jackson, P Dewan, IS Anand, J Bělohlávek, O Bengtsson, RA de Boer, ... Circulation 142 (11), 1040-1054, 2020 | 126 | 2020 |
| Mutational and Computational Analysis of the α1b-Adrenergic Receptor: INVOLVEMENT OF BASIC AND HYDROPHOBIC RESIDUES IN RECEPTOR ACTIVATION AND G PROTEIN COUPLING* 210 PJ Greasley, F Fanelli, A Scheer, L Abuin, M Nenniger-Tosato, ... Journal of Biological Chemistry 276 (49), 46485-46494, 2001 | 104 | 2001 |
| Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability AJ King, M Siegel, Y He, B Nie, J Wang, S Koo-McCoy, NA Minassian, ... Science translational medicine 10 (456), eaam6474, 2018 | 84 | 2018 |
| Big pharma screening collections: more of the same or unique libraries? The AstraZeneca–Bayer Pharma AG case T Kogej, N Blomberg, PJ Greasley, S Mundt, MJ Vainio, J Schamberger, ... Drug discovery today 18 (19-20), 1014-1024, 2013 | 77 | 2013 |
| Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes CCJ Dekkers, CD Sjöström, PJ Greasley, V Cain, DW Boulton, ... Diabetes, Obesity and Metabolism 21 (12), 2667-2673, 2019 | 74 | 2019 |
| Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus AS Go, J Yang, TC Tan, CS Cabrera, BV Stefansson, PJ Greasley, ... BMC nephrology 19, 1-13, 2018 | 70 | 2018 |
| Scaffold hopping, synthesis and structure–activity relationships of 5, 6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists J Boström, K Berggren, T Elebring, PJ Greasley, M Wilstermann Bioorganic & medicinal chemistry 15 (12), 4077-4084, 2007 | 67 | 2007 |
| Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the … RA Scholtes, MHA Muskiet, MJB van Baar, AC Hesp, PJ Greasley, ... Diabetes Care 44 (2), 440-447, 2021 | 66 | 2021 |
| N-Arachidonoyl-l-Serine is Neuroprotective after Traumatic Brain Injury by Reducing Apoptosis A Cohen-Yeshurun, V Trembovler, A Alexandrovich, E Ryberg, ... Journal of Cerebral Blood Flow & Metabolism 31 (8), 1768-1777, 2011 | 62 | 2011 |
Hiddo Lambers HeerspinkUniversity of GroningenVerified email at umcg.nl
